CD19 CAR-T for lymphoma: real-world experience in the UK

(6:1econd)

CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALL

(2:36)

CD19 CAR T-cell therapy for lymphoma

(2:55)

CD19 Targeted CAR T-cell Therapy in LBCL

(45:46)

Dr. Shah on Differences Between Anti–CD19 CAR T-Cell Therapies

(1:29)

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

(45)

Outcomes in patients with double refractory DLBCL receiving third-line CD19 CAR-T therapy

(2:9)

Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies

(2:37)

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s Experience

(57:3)

CD19 CAR-T in lymphoma patients in the UK

(10:22)

Development of a novel CD19 CAR with improved functionality

(2:54)

CD19 and CD20 CAR T-cell therapy for non-Hodgkin lymphoma

(2:22)

CD19 CAR-T for CNS lymphoma

(1:39)

Clinical data for CD19-directed CAR T-cell products in ALL

(2:26)

Anti-CD19 CAR-T for Richter’s transformation: an international multicenter retrospective study

(2:41)

Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL

(56)

CD19 CAR T Cell Therapy in SLE (9.16.2022)

(18:59)

The importance of assessing response to CD19 CAR-T therapy in LBCL to confirm disease persistence

(1:59)

Prior blinatumomab use impacts CD19-CAR T-cell therapy response rates in R/R ALL

(3:42)

Exploring novel humanized anti-CD19 CAR-T cells as a strategy to minimize CRS and other toxicities

(1:38)